Market Cap 38.55M
Revenue (ttm) 0.00
Net Income (ttm) -6.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,346,000
Avg Vol 3,637,680
Day's Range N/A - N/A
Shares Out 73.54M
Stochastic %K 42%
Beta 9.08
Analysts Strong Buy
Price Target N/A

Company Profile

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha,...

Industry: Biotechnology
Sector: Healthcare
Phone: 833 931 6330
Address:
13576 Walnut Street, Suite A, Omaha, United States
Latest News on KLTO
No data available.